CRISPR Therapeutics to Speak at Bank of America Health Care Conference 2024

CRISPR Therapeutics, a biopharmaceutical company listed on Nasdaq under the ticker symbol CRSP, is committed to developing groundbreaking gene-based treatments for serious diseases. On May 09, 2024, the company announced that its senior management team would be presenting at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m. ET. This presentation will be available via a live webcast on the "Events & Presentations" page of the Investors section on the company's website. A replay will be accessible on the same webpage for 14 days after the presentation.

CRISPR Therapeutics has taken significant strides since its foundation over a decade ago. Originally a research-focused entity, the company has evolved to celebrate the historic approval of the first-ever CRISPR-based therapy. The company's portfolio now includes a wide array of product candidates addressing various disease areas such as hemoglobinopathies, oncology, regenerative medicine, cardiovascular diseases, autoimmune disorders, and rare diseases.

In 2018, CRISPR Therapeutics pioneered the clinical introduction of the first-ever CRISPR/Cas9 gene-edited therapy. This groundbreaking therapy was designed to explore treatments for sickle cell disease and transfusion-dependent beta thalassemia. By late 2023, CASGEVY™ (exagamglogene autotemcel) had gained approval in several countries for treating eligible patients with these conditions. This milestone underscores the immense potential of CRISPR technology, which has been recognized with a Nobel Prize, to revolutionize biomedical research and create transformative medicines.

To enhance and broaden its efforts, CRISPR Therapeutics has formed strategic alliances with leading companies in the industry, including Bayer and Vertex Pharmaceuticals. These collaborations aim to propel the development and commercialization of innovative gene-based therapies. The company’s headquarters are in Zug, Switzerland, and it operates a wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., with research and development activities based in Boston, Massachusetts, and San Francisco, California. Additionally, it maintains business offices in London, United Kingdom.